You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
ECCCHO: Effective Combat Casualty Care Handoff Operations
SBC: TIER 1 PERFORMANCE SOLUTIONS LLC Topic: DHA17B002Approximately 70% of sentinel events in medical care are related to communication mishaps, and despite regular and frequent occurrence, an even higher percentage (80%) of severe medical errors are related to miscommunication during handoffs (i.e., the transferring of information, responsibility, and authority for patient care from one provider to another). The TiER1 team proposes to address challe ...
STTR Phase I 2018 Department of DefenseDefense Health Agency -
Rapid SERS-based Detection of Sepsis and TBI Biomarkers
SBC: Ionica Sciences, Inc Topic: DHA17B004Traumatic brain injury (TBI) often occurs when a sudden trauma or head injury disrupts the function of the brain. Common causes of TBI include damage caused by explosive devices, falls and vehicle or motorcycle accidents. Sepsis is the result of a massive immune response to bacterial infection that gets into the blood. Sepsis often leads to organ failure or injury, and has always been a significan ...
STTR Phase I 2018 Department of DefenseDefense Health Agency -
Development of KLS-13019 for Chemotherapy Induced Peripheral Neuropathy and Drug Dependence
SBC: KannaLife Sciences Inc. Topic: NIDAChemotherapy induced peripheral neuropathyCIPNcan be a chronicseverely debilitating consequence of cancer therapy for which there are no effective management strategiesMoreoverupwards ofof CIPN patients reported using prescription opioids for pain management despite the fact that there is only weak evidence that long term continuation of opioids provides clinically significant pain relief in these ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Commercialization of a Rapid Blood Test for Traumatic Brain Injury
SBC: Fawkes Biotechnology, LLC Topic: 100Traumatic brain injuryTBIis a substantial health care issue affecting both civilian and military populationsAlthough extremes of head injury are recognizablemild to moderate TBImmTBIis more difficult to diagnose leading to a need for the identification of circulating biomarkers of brain injury that may facilitate early identificationUsing a rat model of TBI we identified a novel marker of neuronal ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
A universal eye drop adherence monitor to measure and improve adherence to ocular medications
SBC: Universal Adherence LLC Topic: NProject Summary Abstract Universal Adherence is an emerging medical device company dedicated to improving adherence to ocular medications through innovative technical solutionsOur proposed Devers Drop DeviceDwill accurately track when a patient removes an eye drop bottle capcommunicate usage data wirelessly to a database that researchers can accessand send alerts to patients when a medication is d ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
MtLDL detection to diagnose childhood tuberculosis
SBC: CHRONUS PHARMACEUTICALS, INC. Topic: NIAIDProject SummaryChildhood TB is estimated to contributeof the disease burden in high burden settingswith approximately a million cases per year inworldwideExisting gold standard diagnostic culture tools fail to confirm TB in most childrenwho typically have low bacterial counts and cannot produce sputumMore sensitive and child friendly diagnostic tools are urgently needed to diagnose TB in childrenC ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Production and Characterization of Human Immunoglobulin Producing Goats for Diagnostic Reagents and Therapeutics
SBC: SAB CAPRA, LLC Topic: NIAIDProject Summary A research plan is proposed to engineer goats that produce fully human immunoglobulinThese animals will be evaluated as a candidate platform system for production of both targeted therapeutic immunoglobulin as well as reagent antibodies for standards and controls of serological assays of human clinical samplesPrevious studies have demonstrated that ungulates such as cattle can prod ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
The Kappa Partial Agonist PPL-103 as a Potential Cocaine Abuse Pharmacotherapy
SBC: PHOENIX PHARMALABS, INC. Topic: NIDAAbstract Currentlyclinically used drug abuse medications exist for treatment of addiction to opiatesalcoholand nicotinebut not cocaineThe objective of the proposed project is to test the hypothesis that the partial kappa agonist PPLcan be effective as a pharmacotherapy for treatment of cocaine abuseBecause of chronic drug induced changes in the kappa opioid receptor systemkappa receptor directed c ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Oxidation-resistant Anti-protease Therapy
SBC: LEXEO Therapeutics LLC Topic: NHLBIAbstractLEXEO TherapeuticsLLCis an early stage biotechnology company focused on using gene therapy technologies to protect vulnerable organs from oxidant stressLEXthest LEXEO productis ast in classnext generation gene therapy treatment for alphaantitrypsinAATdeficiencyan autosomal recessive hereditary disorder associated with low serum levels of AATAATSERPINAakDa serine antiprotease produced by th ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
TFEB Activator for Alzheimer's Disease Therapy
SBC: BRILLIANT BIOSCIENCES INC. Topic: NIAOne in ten of the persons ageare affected by Alzheimer s diseaseADcausing enormous social and economic burden to the United StatesTo date only five medications have been approved by the FDA for the treatment of the symptoms of ADbut none of them slows or stops the disease progressionWith the recent repeated failures of AD drugs on thesecretase inhibitorsthe need for an effective AD drug became eve ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health